The Data Management core activities are performed by the Data Management Center of the ECOG- ACRIN Statistics and Data Management Center. The Data Management Center is responsible for collection and processing of data on ECOG-ACRIN studies and for related information systems support. The Center has two components. SDMC-EAMRF at the ECOG-ACRCIN Medical Research Foundation has primary responsibility for therapeutic studies. The SDMC-ACR at the American College of Radiology has primary responsibility for diagnostic and imaging studies. All clinical data on studies activated since the start of the NCTN is collected and managed in Medidata Rave, the NCTN's common Clinical Data Management System. ECOG-ACRIN has been a leader in developing configuration standards and operational procedures for using Rave in the NCTN. Data review procedures are well developed and include clinical review, which is usually performed by study chairs. The Data Management core has established extensive education and training programs for site personnel and investigators. These training programs are an important part of ensuring timely and accurate data submission and review. The data management core has also developed reports for monitoring site performance regarding timeliness and accuracy of data submission, and works with the ECOG-ACRIN Operations on the annual institution evaluation. The Statistics and Data Management Center also fully utilizes standard NCTN tools, such as the Oncology Patient Enrollment Network (the web interface for patient enrollment on NCTN studies), the Cancer Data Standards Repository library of standardized data elements, the common toxicity criteria for adverse events, the CTEP-AERS system for adverse event reporting, which is being integrated into Rave), and the Clinical Data Update System for reporting selected trial and patient data to NCI. The Information Systems group maintains multiple databases, develops and maintains tools for monitoring, reporting, and communication, and has developed infrastructure to support complex trials such as NCI- MATCH.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA180794-06
Application #
9627515
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-04-04
Budget End
2020-02-29
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Estabrook, Ryne; Cella, David; Zhao, Fengmin et al. (2018) Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805. Qual Life Res 27:1589-1597
Harshman, Lauren C; Chen, Yu-Hui; Liu, Glenn et al. (2018) Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol 36:376-382
Henderson, Tara O; Parsons, Susan K; Wroblewski, Kristen E et al. (2018) Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer 124:136-144
Dahlberg, Suzanne E; Gray, Robert J (2018) Pragmatic approaches to address expansion cohort design. Cancer 124:3290-3292
Rakovitch, E; Gray, R; Baehner, F L et al. (2018) Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat 169:359-369
Ristau, Benjamin T; Manola, Judi; Haas, Naomi B et al. (2018) Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. J Urol 199:53-59
Wong, Yu-Ning; Manola, Judith; Hudes, Gary R et al. (2018) Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clin Genitourin Cancer 16:e315-e322
Scott, David W; King, Rebecca L; Staiger, Annette M et al. (2018) High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 131:2060-2064
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Morgans, Alicia K; Chen, Yu-Hui; Sweeney, Christopher J et al. (2018) Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095

Showing the most recent 10 out of 187 publications